Therapy

Do CDK4/6 inhibitors improve upon adjuvant endocrine therapy?

Two phase 3 trials have left physicians and patients in a quandary about the adjuvant use of CDK4/6 inhibitors in endocrine-sensitive breast cancer.

Read More

Atezolizumab trials spark uncertainty and speculation

Two trials suggest we must be somewhat concerned about the chemotherapy partner used with an immune checkpoint inhibitor in patients with advanced triple-negative breast cancer (TNBC) expressing programmed death–ligand 1 (PD-L1).
Read More

Honeybee venom can kill aggressive breast cancer cells

Melittin, a peptide in honeybee venom, selectively targeted HER2- and EGFR-overexpressing breast cancer cells.

Read More

MINDACT Points To Possible Undertreatment Of Younger Women With Luminal Breast Cancer

Adjuvant endocrine therapy alone may be insufficient for some younger women with luminal breast cancer, based to an unplanned analysis of the phase 3 MINDACT trial.
Read More

Targeted Therapies For Metastatic Breast Cancer: The Next Generation

In 2016, an opinion piece published in the journal Nature threw cold water on the concept of precision oncology — tailoring the treatment of individual patients to the genetic characteristics of their tumors.
Read More

Older Breast Cancer Patients Fare Well With Combo Of CDK4/6 Inhibitor And AI

Combination therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor and an aromatase inhibitor (AI) has the same good efficacy but greater toxicity in women with hormone receptor (HR)–positive, HER2-negative advanced breast cancer who are aged 75 years or older, a pooled analysis of randomized controlled trials concluded.
Read More

Treatment Trends And Prognostic Findings Illuminate Male Breast Cancer Journey

Men with breast cancer face an exceptionally challenging journey with fewer signposts to guide the way, compared with their female counterparts.
Read More

Dual MTOR Inhibition Inferior To Single For ER+ Advanced Breast Cancer

mTOR inhibitor vistusertib plus fulvestrant was inferior to everolimus plus fulvestrant in a randomized clinical trial including women with advanced breast cancer, investigators have reported.
Read More